Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 14/20 | 0.76 |
| ▸ | FPR2 | P25090 | 14/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856708 | 1.00 | FPR3 (0.76) | FPR3FPR2ALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL2683287 | 0.87 | FPR3 (0.74) | FPR3FPR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2684819 | 0.86 | FPR3 (1.00) | FPR3FPR2 | |
| SCHEMBL2683884 | 0.85 | FPR3 (1.00) | FPR3FPR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL856921 | 0.84 | FPR3 (0.71) | FPR3FPR2ALDH1A1SMN1; SMN2TAAR1 | |
| SCHEMBL2683547 | 0.84 | FPR3 (0.71) | FPR3FPR2ALDH1A1SMN1; SMN2TAAR1 | |
| SCHEMBL2684094 | 0.82 | FPR3 (1.00) | FPR3FPR2SMN1; SMN2 | |
| SCHEMBL2682189 | 0.82 | FPR3 (1.00) | FPR3FPR2 | |
| SCHEMBL20013750 | 0.78 | ALDH1A1 (1.00) | FPR3FPR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2683323 | 0.76 | FPR3 (1.00) | FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | FPR3 3/4885FPR2 2/4885ALDH1A1 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.